{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bladder+Carcinoma+in+Situ+%28CIS%29", "query": { "condition": "Bladder Carcinoma in Situ (CIS)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 41, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bladder+Carcinoma+in+Situ+%28CIS%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-11T02:26:43.798Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02901548", "title": "Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma in Situ of Bladder", "Bladder Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Cystoscopy with Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2017-02-16", "completion_date": "2021-09-07", "has_results": true, "last_update_posted_date": "2022-07-29", "last_synced_at": "2026-06-11T02:26:43.798Z", "location_count": 2, "location_summary": "Miami Beach, Florida • Tampa, Florida", "locations": [ { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02901548" }, { "nct_id": "NCT00462488", "title": "Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urinary Bladder Cancer", "Bladder Cancer", "Bladder Neoplasms", "Bladder Tumors" ], "interventions": [ { "name": "Vicinium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sesen Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2007-03", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2020-05-12", "last_synced_at": "2026-06-11T02:26:43.798Z", "location_count": 8, "location_summary": "Tallahassee, Florida • Baltimore, Maryland • Lawrenceville, New Jersey + 5 more", "locations": [ { "city": "Tallahassee", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Lawrenceville", "state": "New Jersey" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Springfield", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00462488" }, { "nct_id": "NCT05463796", "title": "InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer Risk", "Cancer Predisposition Syndrome", "Hereditary Cancer Prediction", "Childhood Cancer Survivors", "Adult Cancer Survivors", "IARC Carcinogens", "Smoking History", "Lung Cancer", "Ductal/Lobular Carcinoma", "Barrett Esophagus", "Pancreatic Precursor Lesions", "Colonic Dysplasia/Adenomata", "Non-Alcoholic Fatty Liver Disease", "Non Alcoholic Steatohepatitis", "Cirrhosis", "High Grade Prostatic Epithelial Neoplasia", "High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ", "Adenomatous Hyperplasia", "High-risk Oral Precancerous Diseases", "Melanocytic Lesion, Adult", "Hematologic Malignancy", "Lung; Node", "Serous Tubal Intraepithelial Carcinoma", "Endometrial Intraepithelial Neoplasia", "Cervical and Endocervical Carcinoma in Situ", "Vulvar Intraepithelial Neoplasia", "Nephrogenic Rests", "Benign Bone Lesions With Risk of Malignant Degeneration", "Giant Cell Tumor", "Osteochondroma", "Spitz Nevus" ], "interventions": [ { "name": "Samples", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 5000, "start_date": "2023-04-25", "completion_date": "2032-03-25", "has_results": false, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-06-11T02:26:43.798Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05463796" }, { "nct_id": "NCT04752722", "title": "LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Superficial Bladder Cancer", "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ" ], "interventions": [ { "name": "EG-70 (phase 1)", "type": "DRUG" }, { "name": "EG-70 (phase 2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "enGene, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2021-04-22", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-06-11T02:26:43.798Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04752722" }, { "nct_id": "NCT00006034", "title": "Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "keyhole limpet hemocyanin", "type": "BIOLOGICAL" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Intracel", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-06", "completion_date": "2004-03", "has_results": false, "last_update_posted_date": "2013-05-15", "last_synced_at": "2026-06-11T02:26:43.798Z", "location_count": 1, "location_summary": "Frederick, Maryland", "locations": [ { "city": "Frederick", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006034" }, { "nct_id": "NCT05375903", "title": "A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-muscle Invasive Bladder Cancer", "NMIBC", "Carcinoma in Situ of Bladder", "Bladder Cancer", "Urothelial Carcinoma Bladder", "Urothelial Carcinoma Recurrent" ], "interventions": [ { "name": "UGN-301", "type": "DRUG" }, { "name": "UGN-201", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UroGen Pharma Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2022-06-01", "completion_date": "2026-01-09", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-06-11T02:26:43.798Z", "location_count": 7, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 4 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05375903" }, { "nct_id": "NCT04452591", "title": "Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Muscle Invasive Bladder Cancer", "High-grade Ta/ T1 Papillary Disease Bladder Cancer" ], "interventions": [ { "name": "Cretostimogene Grenadenorepvec", "type": "BIOLOGICAL" }, { "name": "n-dodecyl-B-D-maltoside", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "CG Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2020-10-27", "completion_date": "2031-12-24", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-06-11T02:26:43.798Z", "location_count": 45, "location_summary": "Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04452591" }, { "nct_id": "NCT05951179", "title": "Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-muscle Invasive Bladder Cancer" ], "interventions": [ { "name": "TARA-002", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Protara Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2023-09-15", "completion_date": "2032-03", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-06-11T02:26:43.798Z", "location_count": 40, "location_summary": "Homewood, Alabama • Phoenix, Arizona • Queen Creek, Arizona + 34 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Queen Creek", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05951179" }, { "nct_id": "NCT00538850", "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Fentanyl sublingual spray", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2007-10", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2014-03-05", "last_synced_at": "2026-06-11T02:26:43.798Z", "location_count": 1, "location_summary": "Chandler, Arizona", "locations": [ { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538850" }, { "nct_id": "NCT05085977", "title": "Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-muscle Invasive Bladder Cancer" ], "interventions": [ { "name": "TARA-002", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Protara Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2022-03-10", "completion_date": "2024-10-30", "has_results": false, "last_update_posted_date": "2025-01-27", "last_synced_at": "2026-06-11T02:26:43.798Z", "location_count": 11, "location_summary": "Los Angeles, California • Jacksonville, Florida • New Orleans, Louisiana + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05085977" } ] }